The purpose of this clinical trial is to evaluate the initial safety and efficacy of the ExAblate Model 4000 Type 2.1 surgical device for nucleus accumbens (NAc) neuromodulation in patients with psychostimulant use disorder (PUD).
Adults between the ages of 19 and 60
Subject is diagnosed with a DSM-5 psychostimulant* use disorder (PUD) by a board certified psychiatrist.
Subject is currently receiving standard substance use disorder inpatient treatment or an intensive outpatient program
Subject has been off psychostimulants and other illicit drugs, confirmed via urine toxicology screen
Subject with standard contraindication for MR imaging, such as non-MRI compatible implanted metallic devices.
Subject with known allergies to the MRI contrast agent gadolinium (Gadovist®) or contraindication (such as untreated hypokalemia).
Subject who are unable or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours)
More than 30% of the skull area traversed by the sonication pathyway is covered by scars, scalp disorder (e.g., eczema), or atrophy of the scalp.
Single group
ExAblate 4000 Type 2.1
DeviceIn treatment arm, the subject will receive device application(bilateral NAc FUS; Visit 2) Subjects will return to the site at Visit 3 (7±2 days post device application), Visit 4 (30±7 days post device application), Visit 5 (90±7 days post device application), and Visit 6 (180±7 days post device application) for safety and efficacy assessments.
Success rate of psychostimulant abstinence (%)
Percentage of subjects with no detectable psychostimulants and other illicit drugs by urine toxicology screening after application
Time to relapse (in days)
Time in days from active sonication to the first positive urine toxicology result indicating psychostimulant relapse. Participants without a positive urine toxicology result are followed through Day 180.
Visual Analog Scale rating of craving severity
Change in substance craving visual analog scale (VAS, 0-10) score after device application. Craving is rated on a 0-10 visual analog scale, where 0 indicates no craving and 10 indicates the strongest craving ever.
Assessments related to mood/anxiety/attention/impulsivity
Change (in points) in assessments of mood/anxiety/attention/impulsivity
Assessment of cognitive function
Change in Cognitive Function Assessment (points) Post-device application
Click on the lead sponsor to view all of their trials.
